Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kay Seden

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
AIDS (London, England)|May 31, 2013
Drug-drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical DiseasesKay Seden, Saye Khoo, David Back, et al.
Plos One|March 5, 2011
Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohortGabriel Kigen, Sylvester Kimaiyo, Winstone Nyandiko, et al.
BMJ Open|January 12, 2013
Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West EnglandKay Seden, Jamie J Kirkham, Tom Kennedy, et al.
Drug Safety|September 14, 2020
The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by WomenEva Agnes Odongpiny Laker, Arnold Arinaitwe, Noela Owarwo, et al.
BMC Infectious Diseases|November 14, 2021
Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in UgandaAdelline Twimukye, Miriam Laker, Eva Agnes Laker Odongpiny, et al.
HIV Medicine|June 2, 2019
British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019Margherita Bracchi, Clare van Halsema, Frank Post, et al.
The Lancet. HIV|May 11, 2020
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trialKenneth Kintu, Thokozile R Malaba, Jesca Nakibuka, et al.
The Journal of Antimicrobial Chemotherapy|July 12, 2024
Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan AfricaDaniel Kiiza, Danial Rostami-Hochaghan, Yussif Alhassan, et al.
The Lancet. HIV|July 29, 2022
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled studyThokozile R Malaba, Irene Nakatudde, Kenneth Kintu, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
AIDS (London, England)|May 31, 2013
Drug-drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical DiseasesKay Seden, Saye Khoo, David Back, et al.
Plos One|March 5, 2011
Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohortGabriel Kigen, Sylvester Kimaiyo, Winstone Nyandiko, et al.
BMJ Open|January 12, 2013
Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West EnglandKay Seden, Jamie J Kirkham, Tom Kennedy, et al.
Drug Safety|September 14, 2020
The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by WomenEva Agnes Odongpiny Laker, Arnold Arinaitwe, Noela Owarwo, et al.
BMC Infectious Diseases|November 14, 2021
Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in UgandaAdelline Twimukye, Miriam Laker, Eva Agnes Laker Odongpiny, et al.
HIV Medicine|June 2, 2019
British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019Margherita Bracchi, Clare van Halsema, Frank Post, et al.
The Lancet. HIV|May 11, 2020
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trialKenneth Kintu, Thokozile R Malaba, Jesca Nakibuka, et al.
The Journal of Antimicrobial Chemotherapy|July 12, 2024
Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan AfricaDaniel Kiiza, Danial Rostami-Hochaghan, Yussif Alhassan, et al.
The Lancet. HIV|July 29, 2022
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled studyThokozile R Malaba, Irene Nakatudde, Kenneth Kintu, et al.
Pageof 2